Latest Articles

Publication Date
Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.

Endometriosis is a chronic, estrogen-dependent disorder defined by ectopic endometrial-like tissue growth, persistent inflammation, and aberrant innervation. Emerging evidence indicates that disease progression and symptom severity are driven by a …

Published: May 19, 2026, midnight
Healthcare Professionals' Experiences of Telemedicine Supporting Outpatient Endometriosis Care: A Qualitative Study of Tele-Patient-Reported Outcome Measures.

Telemedicine may advance endometriosis care, but few initiatives are integrated in outpatient follow-up. A novel telemedicine approach-tele-patient-reported outcome measures (telePROM)-includes an endometriosis-specific questionnaire and phone and video consultations combined with …

Published: May 19, 2026, midnight
Ultrasound-Guided Diagnosis and Treatment of Postsurgical Peripheral Nerve Entrapment in Persistent Pelvic Pain.

Postsurgical peripheral neuropathic pain may be overlooked in patients with chronic pelvic and inguinal pain when overlapping etiologies coexist. This case report describes an ultrasound-guided diagnostic and therapeutic approach for …

Published: May 19, 2026, midnight
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters

Merck's drug helps uterine cancer patients live longer in late-stage trial Reuters

Published: May 18, 2026, 2 p.m.
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive

Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive

Published: May 18, 2026, 1:38 p.m.
The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy - Pharmacy Times

The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy Pharmacy Times

Published: May 18, 2026, 12:19 p.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Efficacy of different pretreatments in IVF outcomes in patients with endometriosis: A systematic review and network meta‑analysis.

To investigate the efficacy of different pretreatment protocols for women with endometriosis undergoing IVF. We systematically searched the Cochrane Library, PubMed, Medline, and Embase from inception to April 30, 2025, …

Published: May 18, 2026, midnight
Challenging the paradigm that neonatal uterine bleeding represents the first menstrual episode.

Neonatal uterine bleeding (NUB) has been hypothesized as a relatively common early-life event potentially linked to the later development of endometriosis through retrograde menstruation. However, its true prevalence and biological …

Published: May 18, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!